Navigation Links
i. Series Platelet Agitator PF96i

Productsi. Series Platelet Agitator PF96i
Company Helmer, Inc.
Item i. Series Platelet Agitator PF96i
Features 
  • Heavy-duty ball bearing gear motor.
  • Internal fan.
  • Delrin rollers and glides allow the drawer storage platform to agitate smoothly.
  • Sturdy, one piece perforated drawers for uniform air circulation.
  • Drawers are removable for storage of any size product.
  • Drawer label holders provided for each agitator drawer.
Description Helmer platelet agitators offer a wide range of storage capacities. Delrin rollers and glides allow the drawer storage platform to agitate smoothly, eliminating the need for ball bearings which wear down and squeak. Sturdy, one-piece perforated drawers with non-slip textured coating provide uniform air circulation for your platelets.

i.Series platelet agitators feature a built-in motion alarm with adjustable volume. An alarm will sound when the side- to-side motion is not detected. When placed in an i.Series incubator, the agitator can be monitored by the i.Center with the AgiTrak system.

Info Helmer, Inc.
Customer Service: (800) 743-5637
Web site: http://www.helmerinc.com

Related medicine products :

1. Series 20000 Legacy
2. Series 24 Watt Sealed CO2 OEM Lasers
3. M/MK Series
4. EA/EKA Series
5. EHS Series
6. MLS-Series Top-Loading Autoclaves
7. Blood Coagulation Analyzer CG Series
8. Cytomics FC 500 Series
9. Series 400 Aggregometers
10. Series 500 Aggregometers
11. Series 490 Low Cost Automatic Optical Aggregometers
Near and far chart set provides letter and number matrix for testing and accommodative vision training. Set includes 1-8 1/2 X 11 chart on white card with black print and 2-3X5 laminated white card w
Rosenbaum card fits in the pocket (3.5 by 6.5") and shows point, Jaeger and distance equivalents from 20/800 to 20/20. Uses numbers, directional Es and XO patterns. For use at 14" (35 mm). Includes f
...ally designed to be a corrected Rosenbaum card. Th...as noted by Horton and Jones in 1997 and others) h... because of the lack of standards associated with ...xaminer can measure a patients single letter near ...
...ding card was designed by James Lebensohn, MD and ...uding words, numbers and OX symbols. Optotypes inc... 20/50, 20/40, 20/30, 20/25, and 20/20. Notation e...metric, Jaeger, point size and visual efficiency p...
Medicine Products:
(Date:11/22/2008)...elves from stroke, heart attack, , , FR...cine,s mantras: If you have high blood pressure, t...t on your risk of stroke, heart disease and more. ...sure still aren,t doing a good enough job controll...ntrol and Prevention study. , "High blood pres...
(Date:11/21/2008)... from basic training and now serving overseas, mee... saved by donating his rare blood type. , ...a (PRWEB) November 21, 2008 -- A local Korean woma...ved her life, met for the first time when she visi...n Tamarias Pope, 8th Security Forces Squadron, met...
(Date:11/21/2008)...her to stop abusive behavior, experts say , ... that was once dismissed as "kids being kids" is n...search shows the negative effects on both the bull...ools, parents and even kids themselves are coming ...or. , "Bullying shouldn,t be considered a norm...
(Date:11/21/2008)...as Health Science Center at Houston will launch a ...(TEXAS), to promote geriatrics training for physic...he Donald W. Reynolds Foundation and $1.25 million... geriatric medicine principles to everyone from th...ians. With the reach of Lyndon B. Johnson General ...
Breaking Medicine News(10 mins):Health News:High Blood Pressure Stalks Many Americans 2Health News:High Blood Pressure Stalks Many Americans 3Health News:Life-Saving Airman, Leukemia Patient Meet for First Time 2Health News:Life-Saving Airman, Leukemia Patient Meet for First Time 3Health News:Getting Tough on Bullying 2Health News:Getting Tough on Bullying 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4
...y’s immune system and help protect the body agains...a. A new study shows promising treatment for acute...ficially stimulating natural killer cells from a p...hod could help treat patients with the highly fata...
...say autistic boys with language problems might hav...age-related disorder known as Specific Language Im...s could help specialists better understand autism ...r individual components of the condition. Research...
...s a man’s disease, but recent reports suggest it i... is helping to identify which women are at highest...he medical records of nearly 2,400 women taking pa...ne Replacement Study (HERS), postmenopausal women ...
...implanted heart-assist devices, such as pacemakers...ance imaging .// Pacemakers and defibrillators are...late an abnormal heartbeat known as arrhythmia. Re...he electromagnetic fields of the MRI may heat up m...
Other Medicine News:
(Date:11/20/2008)...RNewswire-FirstCall/ -- Duska Therapeutics,Inc.,...it has submitted its,pivotal Phase 3 ATPace clini...tocol Assessment (SPA) procedure with the U.S. Foo... to securing an agreement with the FDA, Duska inte...nd, placebo-controlled and randomized Phase 3,cli...
(Date:11/20/2008)...e/ -- Clinical data from a prospective,registry p...ium shows DVT,treatment with the Trellis(R) Perip... (Santa Clara, CA) successfully breaks up the bloo... This technique, called isolated pharmacomecha...kly and safely than current catheter-directed thro...
(Date:11/20/2008)... 20 The Scandinavian-based drug,d...esults of studies on its,lead antimicrobial candi...,the studies showed that the novel lytic peptido...significantly better towards killing Staphylococcu... gold standard drugs. In,addition to this it has ...
(Date:11/19/2008)...19 Amgen,(Nasdaq: AMG... subsidiary of,Takeda Pharmaceutical Company Limi...in the Phase 3 MONET1 trial evaluating motesanib (...platin for the first-line treatment of,advanced n...rily suspended,following a planned safety data re...
Breaking Medicine Technology:Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7International Society of Hair Restoration Surgery and Istituto Dermopatico dellImmacolata Host Made In Italy 3A Hair Restoration Live Video Surgery Wo 19268 1International Society of Hair Restoration Surgery and Istituto Dermopatico dellImmacolata Host Made In Italy 3A Hair Restoration Live Video Surgery Wo 19268 2Personalized Plates for Picky Palates 3A Moms can Satisfy all With One Recipe Four Ways 19266 1Personalized Plates for Picky Palates 3A Moms can Satisfy all With One Recipe Four Ways 19266 2NightHawk Radiology Holdings Inc Announces Dutch Tender Offer for Its Common Stock 19264 1NightHawk Radiology Holdings Inc Announces Dutch Tender Offer for Its Common Stock 19264 2NightHawk Radiology Holdings Inc Announces Dutch Tender Offer for Its Common Stock 19264 3NightHawk Radiology Holdings Inc Announces Dutch Tender Offer for Its Common Stock 19264 4StemCor Systems Inc Awarded NIH SBIR Grant for Bone Marrow Aspiration Platform 5376 1StemCor Systems Inc Awarded NIH SBIR Grant for Bone Marrow Aspiration Platform 5376 2StemCor Systems Inc Awarded NIH SBIR Grant for Bone Marrow Aspiration Platform 5376 3
...nal protection against,infection with virus types ...idate vaccine, PHILADELPHIA, June 27, 2007 /PRNews...s of a Phase III study show that,CERVARIX(R), the ...,provides up to 100 percent protection against adv...on types of human papillomavirus,types 16 and 18....
...h VELCADE, cyclophosphamide,and prednisone alive ...ire-FirstCall/ -- Millennium,Pharmaceuticals, Inc....m clinical trials of VELCADE based therapies that ...(1) (CR) rates in previously,treated multiple myel...t the prestigious 11th International Myeloma Works...
Other Medicine Technology:Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 2Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 3Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 4Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 5Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 6Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 7Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 2Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 3Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 4Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 5Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 6